Paige Britt

Ultrasensitive ctDNA analysis reveals early predictive insights for immunotherapy outcomes in advanced solid tumors, enhancing patient management and survival predictions.

Interim results reveal RAD 101's promising potential in accurately diagnosing brain metastases, enhancing treatment decisions for patients.

PLT012, a groundbreaking anti-CD36 antibody, enters clinical trials to enhance immune responses in solid tumors, promising new hope for cancer treatment.

Roxadustat receives orphan drug designation for myelodysplastic syndromes, highlighting its potential to improve transfusion independence in patients.

A groundbreaking blood test for early breast cancer detection shows exceptional accuracy, outperforming traditional mammography, especially in dense breast tissue.

FDA approves T-DXd plus pertuzumab for HER2-positive metastatic breast cancer, showing significant improvements in progression-free survival and response rates.

A phase 3 study is evaluating olverembatinib with chemotherapy for treating Philadelphia chromosome–positive acute lymphoblastic leukemia, showing promising efficacy and safety.

New research reveals hormone replacement therapy may lower breast cancer risk in BRCA carriers, challenging existing medical guidelines on HRT use.

FDA and EMA approve AVC-203, a groundbreaking CAR-T therapy targeting B-cell malignancies, promising enhanced safety and scalability for patients.

Patients in the DESTINY-Breast09 trial report improved quality of life with T-DXd plus pertuzumab, highlighting distinct side effect profiles compared to standard care.

The MANIFEST-2 trial reveals that pelabresib combined with ruxolitinib significantly improves outcomes for myelofibrosis patients compared to standard treatments.

GLPG5101 shows promising efficacy and safety in treating relapsed/refractory non-Hodgkin lymphoma, achieving high response rates and rapid manufacturing.

MVR-T3011 shows promising efficacy in treating high-risk, BCG-unresponsive bladder cancer, with high response rates and favorable safety profiles.

Silevertinib shows promising antitumor activity in NSCLC and plans for a phase 2 trial in glioblastoma, targeting unmet oncology needs.

LP-184 shows promising efficacy and safety in heavily pretreated advanced cancer patients, paving the way for innovative biomarker-driven therapies.

JANX007 shows promising efficacy and manageable safety in treating metastatic castration-resistant prostate cancer, with significant PSA reductions and durable responses.

Sacituzumab tirumotecan shows promising antitumor activity in advanced urothelial carcinoma, offering hope for patients with limited treatment options.

Ipatasertib shows promising efficacy in heavily pretreated patients with AKT1E17K mutations, highlighting its potential in diverse tumor types.

A clinical trial of the menin inhibitor DS-1594b in patients with relapsed leukemia has been terminated due to inefficacy, revealing safety challenges and insights for future therapies.

Givastomig shows promising antitumor activity and a manageable safety profile in patients with CLDN18.2-positive gastroesophageal carcinoma.

The FDA approves pegfilgrastim-unne, enhancing treatment options for cancer patients at risk of febrile neutropenia during chemotherapy.

Tovorafenib shows promising long-term efficacy for pediatric low-grade glioma, with significant treatment-free intervals and manageable safety profile.

New findings from the TEM-GBM study reveal promising survival rates for patients with glioblastoma treated with the experimental gene therapy Temferon.

The OptiTROP-Lung05 trial shows promising results for sacituzumab tirumotecan combined with pembrolizumab in treating advanced non–small cell lung cancer.

Emerging research highlights the challenges and potential of ctDNA in managing minimal residual disease in breast cancer, paving the way for innovative treatment strategies.

Circulating tumor DNA (ctDNA) revolutionizes minimal residual disease detection, offering a less invasive, real-time method to monitor cancer and guide treatment.

AVZO-103 receives FDA fast track designation, offering hope for advanced urothelial cancer patients previously treated with enfortumab vedotin.

The PACIFIC-2 trial reveals that durvalumab with chemoradiotherapy offers no survival benefits for stage 3 NSCLC and increases treatment-related risks.

Selinexor-based therapies enhance T-cell activation in multiple myeloma patients, revealing potential strategies for improving treatment efficacy and overcoming resistance.

A recent study reveals cognitive behavioral therapy significantly enhances lung cancer patients' ability to manage dyspnea and anxiety, improving overall quality of life.